Connect Sign InPGx and TDM in Psychopharmacology
The optimization of pharmacy decisions is often based on trial-and-error, which may require several weeks to months for many drugs used in psychiatry due to less than desirable response, side effects, and potentially life-threatening toxicity. There are many medications available to treat depression, anxiety, schizophrenia, attention deficit and other behavioral health conditions. Research has shown that pharmacogenomics (PGx) and therapeutic drug monitoring (TDM) can help to inform drug and dose selections. This presentation will provide a background on PGx and TDM laboratory tests, along with some examples of how these tools are relevant to behavioral health.
Dr. Gwendolyn A. McMillin is the scientific director of the mass spectrometry platform at ARUP Laboratories as well as the medical director of clinical toxicology and pharmacogenomics. She is also a professor at the University of Utah School of Medicine. Dr. McMillin received her doctorate degree in pharmacology from the University of Utah, where she also completed a clinical chemistry fellowship. Dr. McMillin is board certified in clinical chemistry and toxicological chemistry. Her research interests include pharmacogenomics, newborn drug exposures, and analytical methods. She is the recipient of the Past Chair award, the Ellis Benson Young Investigator award, and the Outstanding Speaker award.
